- Intranasal zavegepant 10 mg met the study's co-primary endpoints and demonstrated statistically significant superiority versus placebo on a total of 15 consecutive, prespecified primary and secondary outcome measures in the acute treatment of migraine
- Zavegepant showed ultra-rapid pain relief at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose
- Biohaven plans to file a New Drug Application for zavegepant with the U.S. Food and Drug Administration in 1Q2022
PR Newswire
NEW HAVEN, Conn., Dec. 6, 2021